Your Messages Inbox
Your Article Summary
See Latest ArticlesOctober 14, 2009New Data Showed Type 2 Diabetes Patients Experienced Greater Blood Sugar Reductions when Treated with ACTOplus met (pioglitazone HCl and metformin HCl) as Initial Therapy Compared to Either Component Alone
Takeda Pharmaceuticals North America, 10/16/09
A study, published online in the journal Current Medical Research and Opinion, showed that a greater percentage of patients with type 2 diabetes treated with the fixed–dose combination ACTOplus met as initial therapy reached the study goal of hemoglobin A1c (HbA1c) of <7 percent compared to either component alone. Safety and tolerability of ACTOplus met therapy were evaluated by rate of drug discontinuation and treatment–emergent adverse events.
Today in Drug/Product Approvals...keeping you current
Receive free subspecialty "5-minute updates" via email
Novartis receives approval in the European Union for Onbrez Breezhaler, a new once-daily bronchodilator for patients with COPD
Novartis, 12/04/09
Teva Announces The Submission Of A Biologics License Application (BLA) For XM02 For The Treatment Of Chemotherapy-Induced Neutropenia
Teva Pharmaceutical Industries, 12/02/09
Bayer's Betaferon approved in China for Treatment of Multiple Sclerosis
BayNews International, 12/02/09
Article Search
Sponsor